Re: AGM - Jan 7, 2016 - Details
in response to
by
posted on
Jan 14, 2016 10:03AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Hi longtimerzen.
I went back and checked out the Apsley transaction. Thanks.
Given your longtime involvement with this company (RVX/Zenith) I am really interested in your thoughts regarding the current situation and where you think things are headed.
I'm long on RVX because of the science and feel there will probably be no returns until about 2022 but the returns then could be huge. Of course BETonMACE needs to be successful.
With Zenith I'm hopeful for the science but frustrated by lack of a clear commitment to liquidity but my hands are tied. Nothing I can do.
Hopefully you can share some thoughts.
Regards
Toinv